AstraZeneca Drops Suit After Teva Nixes Generic Faslodex

Law360, New York (June 17, 2011, 12:48 PM EDT) -- A Delaware federal judge dismissed AstraZeneca Pharmaceuticals LP's patent suit against Teva Pharmaceuticals USA Inc. on Thursday, after Teva withdrew its application to make a generic version of AstraZeneca’s breast cancer drug Faslodex.

AstraZeneca and Teva filed a joint stipulation of dismissal on Wednesday, which stated that Teva had agreed to withdraw its abbreviated new drug application. U.S. District Judge Jerome B. Simandle dismissed the case Thursday.

AstraZeneca sued Teva in January 2010, alleging that the company’s plans to produce a generic version of Faslodex would...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.